Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Shares Issued (2019 - 2025)

Historic Shares Issued for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $107000.0.

  • C4 Therapeutics' Shares Issued rose 72307.69% to $107000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $107000.0, marking a year-over-year decrease of 9097.81%. This contributed to the annual value of $778000.0 for FY2024, which is 124137.93% up from last year.
  • C4 Therapeutics' Shares Issued amounted to $107000.0 in Q3 2025, which was up 72307.69% from $111000.0 recorded in Q4 2024.
  • C4 Therapeutics' Shares Issued's 5-year high stood at $873000.0 during Q3 2021, with a 5-year trough of $2000.0 in Q2 2023.
  • Moreover, its 5-year median value for Shares Issued was $166000.0 (2021), whereas its average is $270000.0.
  • As far as peak fluctuations go, C4 Therapeutics' Shares Issued tumbled by 9961.3% in 2021, and later soared by 665000.0% in 2024.
  • Over the past 5 years, C4 Therapeutics' Shares Issued (Quarter) stood at $752000.0 in 2021, then crashed by 93.75% to $47000.0 in 2022, then tumbled by 95.74% to $2000.0 in 2023, then soared by 5450.0% to $111000.0 in 2024, then dropped by 3.6% to $107000.0 in 2025.
  • Its Shares Issued stands at $107000.0 for Q3 2025, versus $111000.0 for Q4 2024 and $13000.0 for Q3 2024.